ONC:NASDAQ
BeOne Medicines AG
360,72 USD
arrow_upward
+0,74%(+2,65) 1 d.
5. 10., 13:41:58 GMT-4 · USD
search
Všetky symboly
| Symbol | Cena | Zmena | % zmeny |
|---|
insights_autoGenerujú sa najdôležitejšie štatistiky pre ONC…
Otvoriť
362,48 USD
Vysoká
362,51 USD
Nízka
356,82 USD
Trh. kap.
43,13 mld.
Priem. obj.
370,83 tis.
Objem
106,18 tis.
Max. za 52 týž.
385,22 USD
Min. za 52 týž.
253,95 USD
Beta
0,61
Akcie v obehu
109,79 mil.
Počet zamestnancov
12 tis.
Otvoriť
362,48 USD
Vysoká
362,51 USD
Nízka
356,82 USD
Trh. kap.
43,13 mld.
Priem. obj.
370,83 tis.
Objem
106,18 tis.
Max. za 52 týž.
385,22 USD
Min. za 52 týž.
253,95 USD
Beta
0,61
Akcie v obehu
109,79 mil.
Počet zamestnancov
12 tis.
Spravodajstvo
Z internetových zdrojov a od spravodajských partnerov
AD HOC NEWS
·
pred 7 hodinami
JPMorgan raises target for BeOne Medicines stock to USD 445.00
TipRanks
·
pred 6 dňami
BeOne Medicines Advances Sonrotoclax Safety Study in Patients With Severe Liver Impairment
TipRanks
·
pred 6 dňami
BeOne Medicines Advances Tacabrutideg With New Liver Function Study
Profil
BeOne Medicines, formerly known as BeiGene, Ltd. is a multinational oncology company. It specializes in the development of drugs for cancer treatment.
Founded in 2010 by chief executive officer John V. Oyler and Xiaodong Wang, the company is headquartered in Cambridge, Massachusetts and has locations on six continents, in over 45 countries. BeOne has a large presence in the Chinese market.
BeOne Medicines has developed several medicines, including tislelizumab, a checkpoint inhibitor, and zanubrutinib, a Bruton's tyrosine kinase inhibitor. On 14 November 2024, the company announced its intention to rebrand as BeOne Medicines. BeOne changed its stock ticker to ONC in January 2025 and redomiciled to Basel, Switzerland in May 2025. Wikipedia
Informácie o subjekte BeOne Medicines AG
Generálny riaditeľJohn Vincent Oyler | John Vincent Oyler
Zamestnanci12 tis.
Dátum založenia28. 10. 2010
Hlavné sídlo-
Odvetvie-